Members of the VCX/Y family have recently been found to be potential immunotherapeutic targets for non-small cell lung cancer (NSCLC) (20, 21) and antibodies directed against the VCX protein were found in these patients, indicating that VCX is immunogenic (22). The gene discussed is VCX; the disease is non-small cell lung carcinoma.